We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





COVID-19 Molecular Diagnostics Fueling Growth of Global Infectious Disease In-Vitro Diagnostics Market

By LabMedica International staff writers
Posted on 30 Apr 2021
The global infectious disease in-vitro diagnostics market is projected to record promising growth over the 2020-2030 period on back of the rising prevalence of infectious diseases around the world, particularly COVID-19.

These are the latest findings of TMR Research (San Francisco, CA, USA), a provider of customized market research and consulting services. More...


Infectious disease in-vitro diagnostic tests perform the function of detecting and identifying the specific infectious agent to establish its origin and enable healthcare professionals to provide the ideal treatment to a patient. These tests can also help in overcoming potential epidemics. This is acting as a vital growth generator for the infectious disease in-vitro diagnostics market. The increasing incidences of infectious diseases and the growing need to tackle them at an early stage have led to tremendous advancements in terms of diagnostics. Infectious disease in-vitro diagnostics is one of them. Thus, this will bring good growth opportunities for the infectious disease in-vitro diagnostics market.

The overwhelming use of infectious disease in-vitro diagnostics in point-of-care testing, central laboratories and others will create immense growth prospects for the market. The growing influence of infectious disease in-vitro diagnostics in detecting a variety of infections such as respiratory viruses, Chlamydia, HPV, Gonorrhea, Clostridium Difficile, MRSA, Streptococcus, Hepatitis B, HIV, Hepatitis C, COVID-19, and others will serve as a vital growth-generator.

The COVID-19 pandemic has wreaked havoc across the globe due to the rising transmission rates and fatality rates. The most efficient way to decrease the mortality rate and prevent infecting others is an intense focus on testing. For COVID-19 testing, RT-PCR (real-time reverse transcription-polymerase chain reaction) is regarded as a gold standard. This testing method is the clinical gold standard for the etiological diagnosis of COVID-19 in which viral DNA is directly detected. RT-PCR tests are being considered as the best option for COVID-19 testing around the world. The growing popularity of these testing methods will create huge growth prospects for the infectious disease in-vitro diagnostics market.

Manufacturers in the infectious disease in-vitro diagnostics market are developing kits that are easier for home use. These kits are designed for home-testing and treatments. Self-testing kits are useful for early diagnosis and consistent patient monitoring. They are also important for curbing costs. Hence, the rising demand for self-testing kits is directly proportional to the growth of the infectious disease in-vitro diagnostics market.

Geographically, North America will continue to dominate the global infectious disease in-vitro diagnostics market with the largest share between 2020 and 2030 on the back of the rising COVID-19 infections across the region. However, the Asia Pacific infectious disease in-vitro diagnostics market is expected to record the fastest growth during this period.

Related Links:
TMR Research


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.